Antisynthetase Syndrome: The Synthesis of a Complex Case
DOI:
https://doi.org/10.24950/rspmi.2575Palavras-chave:
Autoantibodies, Lung Diseases, Interstitial, MyositisResumo
Antisynthetase syndrome is an autoimmune inflammatory myopathy defined by the presence of anti-aminoacyl-tRNA synthetase antibodies, associated with the development of myositis, interstitial lung disease and/or arthritis. It is a rare entity, little known and underdiagnosed, with only two cases published in Portugal.
We report the case of a 62-year-old black woman admitted with interstitial lung disease, associated with respiratory failure and restrictive ventilatory pattern, whose etiological diagnosis was hampered by various complications and obstacles to clinical reasoning. The progression to fibrosis was notorious within a few months and was only halted by the introduction of immunosuppressive therapy following the definitive diagnosis of SAS, confirmed by the presence of anti-PL7 and PL 12 antibodies.
This is the first reported case of antisynthetase co-positivity in the literature, aiming to raise medical awareness about the importance of screening for the presence of antisynthetase antibodies in patients with interstitial lung disease.
Downloads
Referências
Alfraji N, Mazahir U, Chaudhri M, Miskoff J. Anti-synthetase syndrome: a rare and challenging diagnosis for bilateral ground-glass opacities-a case report with literature review. BMC Pulm Med. 2021;21:11. doi: 10.1186/s12890-020-01388-0.
Devi HG, Pasha MM, Padmaja MS, Halappa S. Antisynthetase syndrome: a rare cause for ILD. J Clin Diagn Res. 2016;10:OD08-9. doi: 10.7860/JCDR/2016/16872.7361.
Theilacker LR, Brandão FS, Goulart FV, Vaz JL, D'Almeida LO, da Fonseca Salgado MC. Antisynthetase syndrome: two case report and literature review. Rev Bras Reumatol.;55:177-80. doi: 10.1016/j.rbr.2013.05.007.
Patel P, Marinock JM, Ajmeri A, Brent LH. A review of antisynthetase syndrome-associated interstitial lung disease. Int J Mol Sci. 2024;25:4453. doi: 10.3390/ijms25084453.
Gallay L, Gayed C, Hervier B. Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Curr Opin Rheumatol. 2018;30:664-73. doi: 10.1097/BOR.0000000000000555.
Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol. 2020;34:101503. doi: 10.1016/j.berh.2020.101503.
Wells M, Alawi S, Thin KYM, Gunawardena H, Brown AR, Edey A, et al. A multidisciplinary approach to the diagnosis of antisynthetase syndrome. Front Med. 2022;9:959653. doi: 10.3389/fmed.2022.959653.
Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology. 2017;56:999-1007. doi: 10.1093/rheumatology/kex021.
Cavagna L, Nuño L, Scirè CA, Govoni M, Longo FJL, Franceschini F, et al. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study. Medicine. 2015;94:e1144. doi: 10.1097/MD.0000000000001144.
Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14:264-74. doi: 10.1007/s11926-012-0246-6.
Badshah A, Haider I, Pervez S, Humayun M. Antisynthetase syndrome presenting as interstitial lung disease: a case report. J Med Case Rep. 2019;13:241. doi: 10.1186/s13256-019-2146-0.
Rüegg CA, Maurer B, Laube I, Scholtze D. Jo1-antisynthetase syndrome and severe interstitial lung disease with organising pneumonia on histopathology with favourable outcome on early combined treatment with corticosteroids, mycophenolate mofetil and rituximab. BMJ Case Rep. 2019;12:e231006. doi: 10.1136/bcr-2019-231006.
Monti S, Montecucco C, Cavagna L. Clinical spectrum of anti-Jo-1-associated disease. Curr Opin Rheumatol. 2017;29:612-7. doi: 10.1097/BOR.0000000000000434.
Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med. 2013;107:890-6. doi: 10.1016/j.rmed.2013.02.015.
Mecoli CA, Christopher-Stine L. Management of interstitial lung disease in patients with myositis specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):27. doi: 10.1007/s11926-018-0731-7
Downloads
Publicado
Como Citar
Edição
Secção
Categorias
Licença
Direitos de Autor (c) 2025 Medicina Interna
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
